WuXi, Biologics

WuXi Biologics Denmark Finland Germany Netherlands Sweden United Kingdom China

05.01.2023 - 01:33:24

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platformsWuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net salesView original content:https://www.prnewswire.co.uk/news-releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi---multi-specific-t-cell-engagers-301713524.html

@ prnewswire.co.uk